MedTrace Logo

Luteal Supplementation With Rec-LH After GnRH-agonist Triggering in In Vitro (IVF)

NCT00954811 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2010-01-08

No results posted yet for this study

Summary

Our aim is to access whether we can achieve equivalent pregnancy rates by the addition of six doses of luteal support with recLH after agonist triggering for IVF cycles in the absence of OHSS.

Conditions

  • Pregnancy
  • Pregnancy Loss

Interventions

DRUG

300IU rec-LH

luteal alternate doses

DRUG

progesterone 600mg

luteal support

Sponsors & Collaborators

  • Merck Serono International SA

    collaborator INDUSTRY

  • Universitair Ziekenhuis Brussel

    lead OTHER

Principal Investigators

  • Paul Devroey · Professor or OB-GYN

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
36 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2008-01-31
Completion
2010-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00954811 on ClinicalTrials.gov